ARCA biopharma, Inc. Form 8-K April 18, 2016 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2016 (April 18, 2016) ARCA biopharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-22873 36-3855489 (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer

of Incorporation) Identification No.)

11080 CirclePoint Road, Suite 140, Westminster, CO 80020

(Address of Principal Executive Offices) (Zip Code)

(720) 940-2200

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- £Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- £Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- £Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- £Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 — Other Events

Item 8.01. Other Events.

On April 18, 2016, ARCA biopharma, Inc. ("ARCA") provided a GENETIC-AF clinical trial update. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

99.1 Press Release titled "ARCA biopharma Announces 75 Patient Enrolled in GENETIC-AF Phase 2B/3

Clinical Trial" dated April 18, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 18, 2016

ARCA biopharma, Inc. (Registrant)

By:/s/ Brian L. Selby Name: Brian L. Selby

Title: Vice President, Finance and Chief Accounting Officer

INDEX TO EXHIBITS

Exhibit

Number Description

99.1 Press Release titled "ARCA biopharma Announces 75 Patient Enrolled in GENETIC-AF Phase 2B/3

Clinical Trial" dated April 18, 2016.